HeartSciences to Present at the LD Micro Invitational XIV Conference
HeartSciences to Present at the LD Micro Invitational XIV Conference
Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference.
德克薩斯州南湖，2024年4月2日（GLOBE NEWSWIRE）——由人工智能（AI）驅動的醫療技術公司心臟測試實驗室有限公司 d/b/a HeartSciences（納斯達克股票代碼：HSCS；HSCSW）（“HeartSciences” 或 “公司”）今天宣佈，首席執行官安德魯·辛普森計劃出席LD Simpson 第十四屆微型邀請賽將於美國東部時間2024年4月9日星期二下午5點在紐約索菲特酒店舉行。辛普森先生還將通過會議主持一對一的會議。
A webcast of the presentation will be available on the Company's investor relations website at https://ir.heartsciences.com/.
該演講的網絡直播將在公司的投資者關係網站上播出，網址爲 https://ir.heartsciences.com/。
About HeartSciences
關於《心臟科學》
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test.
Heart Test Laboratories, Inc. d/b/a HeartSciences是一家醫療技術公司，專注於將基於人工智能的創新技術應用於心電圖（也稱爲心電圖），以擴大和改善心電圖的臨床用途。每週進行數百萬次心電圖檢查，該公司的目標是通過使其成爲更有價值的心臟篩查工具來改善醫療保健，尤其是在一線或即時臨床環境中。HeartSciences擁有最大的AI-ECG算法庫之一，並打算在與設備無關的基於雲的解決方案以及低成本的心電圖硬件平台上提供這些AI-ECG算法。HeartSciences與臨床專家合作，確保所有解決方案的設計都符合現有的臨床護理途徑，從而使臨床醫生更容易使用AI-ECG技術來改善患者的護理並帶來更好的療效。HeartSciences 首款獲得 FDA 批准的候選產品 MyoVista wavECG（簡稱 MyoVista）是一種靜息的 12 導聯心電圖，也旨在提供與心臟功能障礙相關的診斷信息，而這些信息傳統上只能通過心臟成像獲得。在同一測試中，MyoVista還提供傳統的心電圖信息。
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences
欲了解更多信息，請訪問： https://www.heartsciences.com。X: @HeartSciences
Safe Harbor Statement
安全港聲明
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2023, filed with the SEC on September 14, 2023, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024, filed with the SEC on March 14, 2024, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
本公告包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的前瞻性陳述。這些前瞻性陳述是根據1995年《私人證券訴訟改革法》的 “安全港” 條款作出的，與公司未來的財務和經營業績有關。除歷史事實陳述外，此處包含的所有陳述均爲 “前瞻性陳述”，除其他外，包括有關HeartSciences信念和期望的陳述。這些陳述基於當前的預期、假設和不確定性，涉及對未來經濟、競爭和市場狀況以及未來業務決策等的判斷，所有這些都很難或不可能準確預測，其中許多是公司無法控制的。這些前瞻性陳述中反映的預期涉及重要的假設、風險和不確定性，這些預期可能被證明是不正確的。投資者不應過分依賴這些前瞻性陳述，這些陳述僅代表截至本新聞稿發佈之日。潛在風險和不確定性包括但不限於HeartSciences於2023年7月18日向美國證券交易委員會（“SEC”）提交的截至2023年4月30日財年的10-K表年度報告、HeartSciences於2023年9月14日向美國證券交易委員會提交的截至2023年7月31日財季10-Q表季度報告中所討論的風險截至2024年1月31日的財季問題，於2024年3月14日向美國證券交易委員會提交，在HeartSciences向美國證券交易委員會提交的其他文件中www.sec.gov。除證券法要求外，公司不承擔更新這些前瞻性陳述的責任。
Contacts:
聯繫人：
HeartSciences
Gene Gephart
+1-682-244-2578 (US)
info@heartsciences.com
心臟科學
Gene Gephart
+1-682-244-2578（美國）
info@heartsciences.com
Investors
Gilmartin Group
Vivian Cervantes
investorrelations@heartsciences.com
投資者
吉爾馬丁集團
薇薇安·塞萬提斯
investorrelations@heartsciences.com
譯文內容由第三人軟體翻譯。